WeightWatchers stock surges 70% after company agrees to buy obesity treatment platform

Health, Fitness & Food

In this article

Shares of WW International, also known as WeightWatchers, skyrocketed Tuesday after the company said it planned to buy Sequence, a telehealth platform that provides treatment for obesity.

The stock closed 79% higher on Tuesday. Its market value stood at more than $488 million.

“It is our responsibility, as the trusted leader in weight management, to support those interested in exploring if medications are right for them,” WW CEO Sima Sistani said in a Monday announcement.

Tuesday’s jump follows a year of sagging performance for the stock. Shares of the company were down 57% over the past year as it struggled to pivot to wellness and move away from weight loss.

Sistani took over as chief executive at the end of February, steering the company back toward weight loss messaging.

The Sequence announcement comes as companies across the weight loss industry look to offer obesity medications as a pathway to customers looking to shed pounds.

The trend has led to a shortage in medications like Ozempic, which are commonly prescribed for Type 2 diabetes.

Products You May Like

Articles You May Like

Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Skillet Lasagna
High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models
I Tried Dopamine Dressing at the Gym and It Changed My Approach to Working Out
Serena Williams Wore the Nike 24.7 Line at the Super Bowl — So We Tried It

Leave a Reply

Your email address will not be published. Required fields are marked *